Lykowska-Szuber Liliana, Skrzypczak-Zielinska Marzena, Zuraszek Joanna, Walczak Michal, Stawczyk-Eder Kamila, Krela-Kazmierczak Iwona, Michalak Michal, Slomski Ryszard, Dobrowolska Agnieszka
Department of Gastroenterology, Dietetics and Internal Diseases, Poznan University of Medical Sciences, Poznań, Poland.
Institute of Human Genetics, Polish Academy of Sciences, Poznań, Poland
Pol Arch Intern Med. 2023 Oct 26;133(10). doi: 10.20452/pamw.16461. Epub 2023 Mar 14.
Crohn disease (CD) is a chronic inflammatory disease characterized by an uncontrolled immune response of the intestinal mucosal cells to antigens derived from the gut lumen. Specifically, the introduction of anti-tumor necrosis factor (TNF) drugs has changed the approach to the treatment of inflammatory bowel disease, and set new therapeutic goals, such as that of controlling clinical symptoms while simultaneously achieving complete endoscopic and mucosal remission. The mechanisms of action of anti-TNF drugs-and consequently the mechanisms of resistance to anti‑TNF therapy-are unknown.
Our study was an attempt to discover whether the potential mechanism of nonresponse may be conditioned by polymorphisms in the genes involved in independent inflammatory or apoptotic pathways.
The study included 196 diagnosed and clinically characterized Polish patients with CD treated with anti‑TNF therapy. Variants rs7539036, rs2041747, rs5746053, rs5746054, rs1061624, rs1143634, rs7896789, and rs55790676 of the FCGR3A, IL1R, TNFRSF1B, IL1B, FAS, and ADAM17 genes were genotyped using Sanger sequencing, and analyzed in the context of response to biologic treatment.
We observed that 33 patients (16.8%) did not respond to the therapy, which was associated with carrying the rs2041747 G allele variant of the ILR1 gene (odds ratio [OR], 3.72; P = 0.009). Moreover, the presence of the FAS rs7896789 homozygous CC genotype correlated with increased susceptibility to the lack of response to the anti‑TNF therapy (OR, 15.22; P = 0.003), whereas TT was identified as a potentially protective genotype.
In patients with CD treated with anti‑TNF drugs, complex pathways with multigene conditioning participate in the mechanism underlying treatment resistance. The genes involved in apoptosis, FAS and ILR1, seem to play an essential role in the lack of response to the treatment, and would be interesting objects of further population and functional research.
克罗恩病(CD)是一种慢性炎症性疾病,其特征在于肠道黏膜细胞对源自肠腔的抗原产生不受控制的免疫反应。具体而言,抗肿瘤坏死因子(TNF)药物的引入改变了炎症性肠病的治疗方法,并设定了新的治疗目标,例如在控制临床症状的同时实现完全内镜和黏膜缓解。抗TNF药物的作用机制以及对抗TNF治疗产生耐药性的机制尚不清楚。
我们的研究旨在探讨无反应的潜在机制是否可能受参与独立炎症或凋亡途径的基因多态性影响。
该研究纳入了196例接受抗TNF治疗的波兰CD确诊患者,并对其进行了临床特征分析。使用桑格测序法对FCGR3A、IL1R、TNFRSF1B、IL1B、FAS和ADAM17基因的rs7539036、rs2041747、rs5746053、rs5746054、rs1061624、rs1143634、rs7896789和rs55790676变体进行基因分型,并结合生物治疗反应进行分析。
我们观察到33例患者(16.8%)对治疗无反应,这与携带ILR1基因的rs2041747 G等位基因变体相关(优势比[OR],3.72;P = 0.009)。此外,FAS rs7896789纯合CC基因型的存在与抗TNF治疗无反应的易感性增加相关(OR,15.22;P = 0.003),而TT被确定为潜在的保护性基因型。
在接受抗TNF药物治疗的CD患者中,多基因调节的复杂途径参与了治疗耐药的机制。参与凋亡的基因FAS和ILR1似乎在治疗无反应中起重要作用,将是进一步人群和功能研究的有趣对象。